

**RECEIVED  
CENTRAL FAX CENTER**

**DEC 18 2003**

PATENT

Attorney Docket No.: 5700.250-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**OFFICIAL**

In re Application of: Jeppesen et al.

Serial No.: 09/995,137

Group Art Unit: 1624

Filed: November 27, 2001

Examiner: Tamthom Ngo Truong

Confirmation No.: 1962

For: Tricyclic Compounds as Nuclear Receptor Modulators

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Status Inquiry (with Attachments – Return PC and Amendment/Response)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner  
Tamthom Ngo Truong

Confirmation No.: 1962, fax number (703) 872-9306 .

Respectfully submitted,

Date: December 18, 2003

  
\_\_\_\_\_  
Dolly Kapadia  
Novo Nordisk® Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Attorney Docket No.: 5700.250-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 09/995,137

Group Art Unit: 1624

Filed: November 27, 2001

Examiner: Truong, Tamthom Ngo

For: Tricyclic Compounds as Nuclear Receptor Modulators

## STATUS INQUIRY

VIA FACSIMILE TO: 703-~~308-4556~~ 872-9306  
18 ~~20~~ PAGESCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The attached response was timely filed in this application as evidenced by the attached USPTO stamped return post card. As of today, December 18, 2003, Applicant has not received any communication regarding this application. Discussion with the Examiner has indicated the response filed September 25, 2003, has not been matched with the application and has not been forwarded to the Examiner for her review.

Please advise the Undersigned of the present status of this application.

Respectfully submitted,

Date: December 18, 2003

Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Attorney Docket No. 5700.250-US  
Patent Application entitled: "Tricyclic Compounds as Nuclear  
Receptor Modulators"  
Applicants: Jeppesen et al.  
USPN: 09/995,137

The USPTO hereby acknowledges receipt of the following:  
1. Certificate of Mailing  
2. Amendment/Response

ROOR/Dokp  
September 25 2003

VIA Express Mail Label

EV246877568US

Attorney Docket No. 5700.250-US  
Patent Application entitled: "Tricyclic Compounds as Nuclear  
Receptor Modulators"  
Applicants: Jeppesen et al.  
USPN: 09/995,137

The USPTO hereby acknowledges receipt of the following:  
1. Certificate of Mailing  
2. Amendment/Response

ROOR/Dokp  
September 25 2003

VIA Express Mail Label

EV246877568US



OCT 02 2003